Aminopyrazine compounds as modulators of an adenosine receptor are provided. The compounds may find use as therapeutic agents for the treatment of diseases mediated through a G-protein-coupled receptor signaling pathway and may find particular use in oncology.
imine-based layered covalent organic framework (COF), containing phenanthroline units as ligands, has allowed the obtention of a heterobimetallated material. Photoactive Ir and Ni fragments were immobilized within the porous structure of the COF, enabling heterogeneous light-mediated Csp3–Csp2 cross-couplings. As radical precursors, potassium benzyl- and alkoxy-trifluoroborates, organic silicates, and proline
含有菲咯啉单元作为配体的亚胺基层状共价有机骨架(COF)的功能化,使得获得异双金属化材料成为可能。光活性 Ir 和 Ni 片段被固定在 COF 的多孔结构内,从而实现异质光介导的 Csp 3 –Csp 2交叉耦合。使用苄基三氟硼酸钾和烷氧基三氟硼酸钾、有机硅酸盐和脯氨酸衍生物作为自由基前驱体,这使得Ir,Ni@Phen-COF具有良好的多功能性。此外,在所有研究的案例中,与类似的均质系统相比,观察到活性和稳定性增强。
Small molecule antagonists of sumo related modification of CRMP2 and uses thereof
申请人:Arizona Board of Regents on Behalf of the University of Arizona
公开号:US11208397B2
公开(公告)日:2021-12-28
This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a piperidinyl-benzoimidazole structure which function as antagonists of small ubiquitin like modifier (SUMO) related modification (SUMOylation) of collapsin response mediator protein 2 (CRMP2), and their use as therapeutics for the treatment of voltage gated sodium channel 1.7 (Nav1.7) related itch, anosmia, migraine event, and/or pain (e.g., neuropathic pain).